Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate

Svobodová, Suzanne; Browning, Judy; MacGregor, Duncan; Pollara, Gabriele; Scolyer, Richard A.; Murali, Rajmohan; Thompson, John F.; Deb, Siddhartha; Azad, Arun; Davis, Ian D.; Cebon, Jonathan

doi:10.1016/j.ejca.2010.09.042

Cited by 50 publications

(57 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T cells and Treg has been associated with poor prognostic factors in breast cancer, including negative hormone receptor status, high tumor grade and lymph node involvement [46]. The proportion of melanoma patients mounting a spontaneous NY-ESO-1-specific antibody response also increases with disease stage [47], and NY-ESO-1-specific T cell responses are known to develop alongside antibody-mediated responses [48,49].…”

Section: Discussionmentioning

confidence: 97%

Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies

McCoy

Nowak

Most

et al. 2012

Cancer Immunol Immunother

View full text Add to dashboard Cite

There is a complex interplay between the immune system and a developing tumor that is manifest in the way that the balance of T cell subsets in the local tumor environment reflects clinical outcome. Tumor infiltration by CD8(+) T cells and regulatory T cells (Treg) is associated with improved and reduced survival, respectively, in many cancer types. However, little is known of the prognostic value of immunological parameters measured in peripheral blood. In this study, peripheral CD8(+) T cells and Treg from 43 patients with malignant mesothelioma or advanced non-small-cell lung cancer scheduled to commence palliative chemotherapy were assessed by flow cytometry and evaluated for association with patient survival. Patients had a higher proportion of peripheral Treg, proliferating CD8(+) T cells and CD8(+) T cells with an activated effector phenotype compared with age-matched healthy controls. Higher proportions of Treg and proliferating CD8(+) T cells were both associated with poor survival in univariate analyses (hazard ratio [HR] 3.81, 95 % CI 1.69-8.57; p < 0.01 and HR 2.86, 95 % CI 1.26-6.50; p < 0.05, respectively). CD8(+) T cell proliferation was independently predictive of reduced survival in multivariate analysis (HR 2.58, 95 % CI 1.01-6.61; p < 0.05). These findings suggest that peripheral CD8(+) T cell proliferation can be a useful prognostic marker in patients with thoracic malignancies planned for palliative chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 97%

Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies

McCoy

Nowak

Most

et al. 2012

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…The NY-ESO-1 protein is known to be markedly immunogenic for numerous advanced and metastatic types of cancer (4,5). NY-ESO-1 is a potential biomarker for the prediction of tumor recurrence and treatment outcomes in a variety of tumors, including gastrointestinal stromal tumors (6) and cutaneous melanoma (7).…”

Section: Introductionmentioning

confidence: 99%

NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Liu

et al. 2011

Oncology Letters

View full text Add to dashboard Cite

Abstract. NY-ESO-1 belongs to the cancer testis antigens (CTA) family, and is identified in a variety of tumors. Certain studies have demonstrated that NY-ESO-1 predicts tumor recurrence and treatment response. No reports are currently available regarding the correlation between NY-ESO-1 and the recurrence of hepatocellular carcinoma (HCC) following surgery. The purpose of the present study was to evaluate the association between NY-ESO-1 and relapse of HCC and to explore the possible mechanisms for this correlation. A total of 120 HCC patients were analyzed for the expression of NY-ESO-1 by immunohistochemistry (IHC). A stable NY-ESO-1 over-expressed HepG2 cell line (ESO-HepG2) was established to determine the biological effects of NY-ESO-1 on cell proliferation, cell cycle and migration by using the xCELLigence DP system, flow cytometry and xCELLigence SP system. NY-ESO-1 was positive in 28 of 120 (23.3%) HCC tumor tissues. NY-ESO-1 was not detectable in adjacent normal liver tissues. A close correlation was found between NY-ESO-1 expression and the recurrence of HCC following surgery (P= 0.007). Kaplan-Meier analysis showed a shorter recurrence-free survival (RFS) for patients positive for NY-ESO-1 (log-rank test, P=0.003). The Cox regression model demonstrated that NY-ESO-1 expression was a significant independent predictor for the recurrence of HCC following curative surgery (P= 0.022). Compared with HepG2 cells, ESO-HepG2 cells have increased migration but not proliferation ability. In conclusion, NY-ESO-1 expression is associated with worse HCC outcome following surgery, and the mechanism for this finding may be that NY-ESO-1 increases tumor cell migration. IntroductionHepatocellular carcinoma (HCC) is the fifth most common cancer in the world and one of the most prevalent malignancies in Asia (1). Current curative treatment options include surgical resection and liver transplantation. Liver transplantation is effective only in the early stages of disease. Surgery is possible in few patients and curative in only a small percentage, due to recurrence following the surgery (2). Besides exploring effective therapeutic methods, investigators are attempting to find biomarkers to predict tumor recurrence. The NY-ESO-1 antigen was originally found in esophageal cancer by serological recombinant cDNA expression cloning (SEREX) and belongs to the cancer/testis antigen (CTA) family (3). NY-ESO-1 expression is restricted to testicular germ cells in normal adult tissues and is found in numerous malignancies including malignant melanoma, hepatoma, breast and lung cancer. The NY-ESO-1 protein is known to be markedly immunogenic for numerous advanced and metastatic types of cancer (4,5). NY-ESO-1 is a potential biomarker for the prediction of tumor recurrence and treatment outcomes in a variety of tumors, including gastrointestinal stromal tumors (6) and cutaneous melanoma (7).Although a number of studies showed inconsistently that NY-ESO-1 is positive in certain HCCs (8-16), two studies have demonstrated that NY-ESO-1 ...

show abstract

“…TMEM31 protein expression in melanoma samples in the present study is notable compared with other known potential CT antigens. In a previous study, the well-characterized CT antigen NY-ESO-1 was demonstrated to be expressed in 30% of stage I and 40% of stage II melanomas tested (18). Other studies revealed that NY-ESO-1 was detected in 36 (11), 31.6 (12) and 45% (14) of melanoma samples tested.…”

Section: Discussionmentioning

confidence: 99%

Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression

Zou

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cancer/testis (CT) antigens are promising targets for immunotherapy due to their restricted expression in the germ cells of the testis in healthy tissue and high immunogenicity. The aim of the present study was to determine whether transmembrane protein 31 (TMEM31) is a CT antigen and to investigate the pattern of TMEM31 expression during the progression of melanoma. The pattern of expression of human TMEM31 mRNA in multiple human tissues was determined through reverse transcription-polymerase chain reaction analysis. TMEM31 protein expression was analyzed in the human testis, in addition to 128 primary melanoma and 64 metastatic melanoma samples through immunohistochemistry analysis. TMEM31 was identified to be predominantly expressed in the testis and weakly expressed in the placenta. In addition, TMEM31 protein expression was detected in 120/190 (63.16%) melanoma samples (primary and metastatic). The intensity of TMEM31 staining in metastatic and primary melanomas was determined through semiquantitative integrated optical density (IOD) analysis, and identified to be significantly increased in metastatic melanoma compared with primary melanoma (0.24±0.03 vs. 0.09±0.01 IOD/area; P<0.001). The expression of TMEM31 protein was significantly increased in metastatic compared with primary melanoma samples (76.56 vs. 56.35%; P=0.017). The results of the present study suggest that TMEM31 is a novel CT antigen that serves an essential role in melanoma metastasis, in addition to being a potential immunotherapeutic target for the treatment of patients with melanoma.

show abstract

Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate

Cited by 50 publications

References 31 publications

Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies

Peripheral CD8+ T cell proliferation is prognostic for patients with advanced thoracic malignancies

NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery

Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression

Contact Info

Product

Resources

About